Bright Wanted US To Purchase Of All Available Remdesivir Stock Early In Coronavirus Outbreak
Executive Summary
The former BARDA director’s whistleblower complaint says he recommended the US government purchase all existing remdesivir doses and set up US-based manufacturing.
You may also be interested in...
After Remdesivir's Emergency Use Authorization, US Gov't Must Now Decide How To Distribute Limited Supply
Gilead's antiviral remdesivir will go to hospitalized severe COVID-19 patients per FDA's EUA. Some cities could receive the medicine with days, but it is not clear how the government will dole out the limited supplies. FDA said it had access to non-public data from a key NIH trial during its EUA review.
AAM Offers Drug Manufacturing Repatriation Plan … For A Price
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.
Gilead’s Major Challenge Is Sustainable Model For Remdesivir
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: